The first blood storage system;
The first commercial artificial kidney;
The first "needleless" IV system;
The first clotting factor for hemophilia;
The first portable kidney dialysis therapy.


Today, Baxter continues to develop innovative treatments and therapies that address unmet medical needs and improve the lives of people worldwide with chronic and acute conditions. For example, the company is studying how adult stem cell therapy may help reverse the damage caused by heart disease, developing pandemic influenza vaccine and exploring regenerative tissue therapies that some day may help patients heal faster. For a more in-depth look at Baxter's history of healthcare innovation, please visit the
company's web site at: www.baxter.com.

About Baxter

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney
disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives. For more information about Baxter, please visit
www.baxter.com.

Back to HCB News

More Voices